Bioanalysis - but not as we knew it: an AstraZeneca perspective of the last 10 years evolution to meet a diversifying portfolio

Bioanalysis. 2019 Apr;11(7):595-599. doi: 10.4155/bio-2019-0037. Epub 2019 Apr 18.
No abstract available

Keywords: CRISPR-Cas9; advanced medicines; antisense oligonucleotides (ASOs); messenger RNA (mRNA); nanomedicine; outsourcing; peptides; portfolio; protein.

MeSH terms

  • Chemistry Techniques, Analytical*
  • Gene Editing
  • Oligonucleotides, Antisense / analysis
  • Oligonucleotides, Antisense / genetics
  • Proteins / analysis
  • Proteins / therapeutic use

Substances

  • Oligonucleotides, Antisense
  • Proteins